These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19254920)

  • 1. Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria.
    Geens E; Geusens P; Vanhoof J; Berghs H; Praet J; Esselens G; Lens S; Dufour JP; Vandenberghe M; Van Mullem X; Westhovens R; Verschueren P
    Rheumatology (Oxford); 2009 May; 48(5):546-50. PubMed ID: 19254920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
    Fautrel B; Flipo RM; Saraux A
    Rheumatology (Oxford); 2008 Nov; 47(11):1698-703. PubMed ID: 18794185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.
    Hur JW; Choe JY; Kim DW; Kim HA; Kim SH; Kim WU; Kim YS; Lee HS; Lee SH; Park SH; Park W; Park YB; Suh CH; Shim SC; Song YW; Yoon BY; Yu DY; Yoo DH
    Rheumatol Int; 2015 Nov; 35(11):1817-23. PubMed ID: 26342296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
    Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
    Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment.
    van Hulst LT; Kievit W; van Bommel R; van Riel PL; Fraenkel L
    Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1407-14. PubMed ID: 21748861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role?
    Rachapalli SM; Williams R; Walsh DA; Young A; Kiely PD; Choy EH;
    Rheumatology (Oxford); 2010 Jul; 49(7):1267-71. PubMed ID: 20008093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease activity-based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade.
    Spijk-de Jonge MJ; Weijers JM; Boerboom LWM; Huis AMP; Atsma F; Van Hulst LTC; van de Laar MAFJ; Hulscher MEJL; van Riel PLCM
    Clin Rheumatol; 2020 Apr; 39(4):1131-1139. PubMed ID: 31997083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern?
    Jerram S; Butt S; Gadsby K; Deighton C
    Rheumatology (Oxford); 2008 Feb; 47(2):180-2. PubMed ID: 18160419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
    Kay LJ; Griffiths ID;
    Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort.
    Benhamou M; Rincheval N; Roy C; Foltz V; Rozenberg S; Sibilia J; Schaeverbeke T; Bourgeois P; Ravaud P; Fautrel B
    J Rheumatol; 2009 May; 36(5):934-42. PubMed ID: 19286850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.
    Vander Cruyssen B; Ribbens C; Boonen A; Mielants H; de Vlam K; Lenaerts J; Steinfeld S; Van den Bosch F; Dewulf L; Vastesaeger N
    Ann Rheum Dis; 2007 Aug; 66(8):1072-7. PubMed ID: 17261531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL
    Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level.
    Riazzoli J; Nilsson JÅ; Teleman A; Petersson IF; Rantapää-Dahlqvist S; Jacobsson LT; van Vollenhoven RF
    Rheumatology (Oxford); 2010 Nov; 49(11):2098-103. PubMed ID: 20615918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belgian rheumatologists' preferences regarding measures of disease activity in patients with rheumatoid arthritis: results from a mixed-methods study.
    De Cock D; Buckinx E; Pazmino S; Bertrand D; Stouten V; Westhovens R; Verschueren P
    Rheumatol Int; 2022 May; 42(5):815-823. PubMed ID: 34687348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.